Lifeway Foods has cancelled a controversial shareholder rights’ plan days before an investor meeting will vote on the make-up of the company’s board.
The so-called ‘poison pill’ measure, in place since 2024, was abandoned in the wake of proxy advisory firm Institutional Shareholder Services (ISS) recommending shareholders vote against Lifeway’s slate of nominees at the meeting on 17 June.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
In a statement yesterday (8 June), Edward Smolyansky, Lifeway’s largest shareholder and the brother of CEO Julie Smolyansky, accused the company’s board of “reactive governance”, saying the board scrapped the plan only when “external pressure leaves no alternative”.
Just Food has approached Lifeway for comment.
Last year, the US kefir maker decided to extend the shareholder rights plan until 29 October 2026. Lifeway adopted the rights plan in November 2024 after turning down takeover interest from Danone.
At the time, Mr. Smolyansky, a long-time, vocal critic of governance at Lifeway, described the extension as the “most brazen example of board and management entrenchment”, adding it was about “protecting control” of the business.
The rights plan was originally adopted to thwart acquisition bids for the business.
French dairy major Danone made two takeover offers for Lifeway in 2024, bids the US group turned down.
The relationship between Lifeway and Danone – which first invested in the business in 1999 – became strained after Lifeway rejected the offers.
However, trhe companies signed a “co-operation” deal in September last year. Under that agreement, Lifeway pledged to “refresh” its board and separate its chair and CEO roles, while both parties agreed to “stay” litigation between the two companies.
In April this year, Lifeway said it would reduce the size of its board from eight to seven directors at its upcoming AGM.
Last month, Danone announced the sale of its entire stake in Lifeway.
On 3 June, Lifeway nominated long-serving director Jason Scher for re-election, saying he provides “historical knowledge and continuity”.
In an SEC filing, the company added: “Accordingly, the board has nominated Mr. Scher to stand for re-election as director of the company at the annual meeting and determined that the size of the board should continue to be eight directors after election of directors at the annual meeting.”
In a statement yesterday, Mr Smolyansky said the decision to pull the poison pill after the ISS recommendation and the renomination of Scher “raise fundamental questions about accountability, transparency, and credibility” at Lifeway.
He is calling on shareholders to vote against the Lifeway slate. “A substantial vote against the incumbent directors would send a clear message that shareholders expect governance commitments to be honoured, shareholder rights to be respected, and accountability to be more than a slogan,” Mr Smolyansky added.
